Exciting news! OncoOne's 1st research article "Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized MIF as an Anticancer Therapeutic" was published online (aacrjournals.org/mct/article/do…) in Molecular Cancer Therapeutics Molecular Cancer Therapeutics TODAY!

Very busy day for our CTO Alexander Schinagl at our poster at #AACR23 today presenting the latest ON203 data, OncoOne‘s lead anti-oxMIF mAb.

Meet OncoOne at #IMMUNOLOGY2023 in Washington DC! Join us to listen to Maroua's talk on our novel antibody ON104 targeting oxidized macrophage migration inhibitory factor (#oxMIF) & meet us at our poster #860. See you on May 12th & 13th! #immunology #inflammation #AAI2023

Excited to share OncoOne’s latest research on " Pretargeted Radioimmunotherapy with an Anti-oxMIF/HSG Bispecific Antibody Demonstrates Efficacy in Murine Models of Cancer " which will be presented by our CTO Alexander Schinagl at #PEGS23. Join him on Tuesday May 16 for his talk.

Proud to announce our team at OncoOne achieved an important milestone! Our first research article, "Preclinical Evaluation of #ON203," is now published in Molecular Cancer Therapeutics's May issue and selected by editors as a First Disclosure. Check out our cover art! aacrjournals.org/mct/issue/22/5

Exciting news! OncoOne's CSO Michael Thiele will be attending #BIOEQUITY in Dublin from May 14-16. Schedule a 1:1 meeting with Michael using the conference partnering tool to learn more about our oxMIF targeted pipeline for cancer and inflammation. Don't miss out!

Discover OncoOne's latest research on oxMIF targeting anti-inflammation therapies at #AAI2023. Join us for Maroua's presentation on ON104, a novel antibody targeting oxMIF, at Poster #P958 in the Exhibition Hall from 2:30 PM - 3:45 PM ET.

Join OncoOne at #AAI2023 for Maroua's talk on "ON104, a novel antibody targeting oxMIF, showing efficacy in preclinical models of chronic inflammation" in the Block Symposium 184 from 3:45-5:45 PM ET in Room 206. Don't miss it!

Join OncoOne's CTO Alexander Schinagl at #PEGS23 Boston for his talk "Pretargeted Radioimmunotherapy with an Anti-oxMIF/HSG Bispecific Antibody Demonstrates Efficacy in Murine Models of Cancer" today from 5:30 to 6:00 PM (ET) in Ballroom A. #oxMIF #PreTargit #radioimmunotherapy

Thrilled to announce the promotion of Christine Landlinger-Schubert to VP Preclinical & Translational R&D at OncoOne! With 15 years of biotech experience, she's shown exceptional leadership skills and her expertise will undoubtedly play a pivotal role in driving OncoOne's success

Exciting news! OncoOne's CEO, Randolf Kerschbaumer, will be attending #BIO2023 in Boston from June 5-8! We're eager to connect with like-minded companies and advance our research in oncology and inflammation. Let's collaborate and innovate together! See you there!

Delighted to announce Friedmund Bachmann’s promotion to VP CMC at OncoOne, effective April 1, 2023! With a remarkable career spanning renowned companies, Friedmund brings expertise in Pharma Sciences and CMC. Congrats, Friedmund!

🌟 Exciting News! Our VP Christine Landlinger-Schubert will present at #ERA2023 Congress in Milan. Her talk on "ON104: A novel bioengineered antibody targeting oxMIF ameliorates experimental Glomerulonephritis" is scheduled for June 16, 12-13:15 CEST.

Exciting News! OncoOne recognized as a Minicorn by Tracxn Soonicorn Awards! Proud to be among Austria's top tech startups. This prestigious award highlights our potential to become a Unicorn, defined by its valuations surpassing one billion dollars in their latest funding.

🎉Celebrate with us! OncoOne turns 5, reflecting on remarkable achievements. €18M funding, 2 optimized anti-oxMIF antibodies (ON203 for cancer, ON104 for inflammation) reaching Phase I readiness and our innovative PreTarg-it Platform. Grateful for our talented and diverse team!

We are delighted to welcome Stephanie Spach, MSc, as the newest member of the OncoOne team, joining us on July 1st. Stephanie will be a valuable addition as a Research Associate in our Biology Team. We are excited to work together towards our common goals.

We are thrilled to present our newsletter for the second quarter of 2023, featuring updates on all our anti-oxMIF programs. Click the link mailchi.mp/98b9e3f15da8/o… to access the newsletter or visit our website oncoone.com. Stay informed and stay connected!

Join us at #FestivalofBiologics in Basel next week! Catch our CSO Michael Thiele's presentation on "Antibody ON104: Tackling Inflammation by targeting oxMIF." Visit poster #76 to see ON104's effectiveness in a mouse arthritis model by Senior Scientist Maroua Ferhat. See you there

Would you like to learn more about OncoOne's current licensing and partnering prospects related to our Anti-oxMIF and PreTarg-it® platforms? Meet us at #BioEurope2023 in Munich next week to discover more.

New First Disclosure: Pretargeted Radioimmunotherapy with the Novel Anti-oxMIF/HSG Bispecific Antibody ON105 Results in Significant Tumor Regression in Murine Models of Cancer. bit.ly/3VkAas3 OncoOne #openaccess